Overview

Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate

Status:
Active, not recruiting

Trial end date:
2021-09-30

Target enrollment:

Participant gender:

Summary

This is a Phase Ib, open label study of ARN-509 administered in combination with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Aragon Pharmaceuticals, Inc.

Treatments:

Abiraterone Acetate
Prednisone